Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amaranthus tuberculatus pollen is an allergenic substance derived from the waterhemp plant, a member of the Amaranthaceae family. It is primarily utilized in the form of an allergenic extract for the diagnosis and treatment of Type I hypersensitivity reactions, including allergic rhinitis, allergic conjunctivitis, and bronchial asthma triggered by seasonal pollen exposure. As a diagnostic tool, it is used in skin prick testing to identify specific IgE-mediated sensitivities. Therapeutically, it is employed in allergen immunotherapy (AIT), where repeated exposure to increasing doses of the allergen modulates the immune response. This process shifts the immune profile from a Th2-dominated allergic reaction to a Th1 and regulatory T-cell (Treg) mediated tolerant state, characterized by reduced IgE production and increased levels of allergen-specific IgG4, thereby providing long-term symptom relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amaranthus tuberculatus pollen.